Additionally, mechanistic studies are needed to better understand the underlying pathways through which SGLT2 inhibitors exert their cardioprotective and potential anti-tumor effects on cancer therapy-induced cardiotoxicity. This evidence concerns the gene SLC5A2 and cancer.